Literature DB >> 15731098

Mice fed lipid-encapsulated Mycobacterium bovis BCG are protected against aerosol challenge with Mycobacterium tuberculosis.

Frank E Aldwell1, Lise Brandt, Clare Fitzpatrick, Ian M Orme.   

Abstract

Mice that consumed a single dose of 10(7) lipid-encapsulated Mycobacterium bovis BCG bacilli showed significant pulmonary and systemic protection against aerosol challenge with M. tuberculosis H37Rv. As an extension of previous challenge studies with virulent strains of M. bovis, this report describes a reduction in M. tuberculosis infection in mice vaccinated orally with lipid-encapsulated BCG comparable to that observed in mice vaccinated subcutaneously with BCG. These results are consistent with the induction of tuberculin-specific cell-mediated immune responses.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15731098      PMCID: PMC1064971          DOI: 10.1128/IAI.73.3.1903-1905.2005

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  16 in total

Review 1.  Stabilisation of BCG vaccines.

Authors:  M Gheorghiu; M Lagranderie; A M Balazuc
Journal:  Dev Biol Stand       Date:  1996

2.  Immunogenicity and protective capacity of Mycobacterium bovis BCG after oral or intragastric administration in mice.

Authors:  M Lagranderie; P Chavarot; A M Balazuc; G Marchal
Journal:  Vaccine       Date:  2000-01-18       Impact factor: 3.641

3.  Comparison of the protective efficacy of bacille calmette-Guérin vaccination against aerosol challenge with Mycobacterium tuberculosis and Mycobacterium bovis.

Authors:  A Williams; A Davies; P D Marsh; M A Chambers; R G Hewinson
Journal:  Clin Infect Dis       Date:  2000-06       Impact factor: 9.079

4.  Immunological basis for reactivation of tuberculosis in mice.

Authors:  J Turner; M Gonzalez-Juarrero; B M Saunders; J V Brooks; P Marietta; D L Ellis; A A Frank; A M Cooper; I M Orme
Journal:  Infect Immun       Date:  2001-05       Impact factor: 3.441

5.  Naturally attenuated, orally administered Mycobacterium microti as a tuberculosis vaccine is better than subcutaneous Mycobacterium bovis BCG.

Authors:  Yukari C Manabe; Cherise P Scott; William R Bishai
Journal:  Infect Immun       Date:  2002-03       Impact factor: 3.441

6.  Single intranasal mucosal Mycobacterium bovis BCG vaccination confers improved protection compared to subcutaneous vaccination against pulmonary tuberculosis.

Authors:  Lihao Chen; Jun Wang; Anna Zganiacz; Zhou Xing
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

7.  Oral delivery of Mycobacterium bovis BCG in a lipid formulation induces resistance to pulmonary tuberculosis in mice.

Authors:  Frank E Aldwell; Ian G Tucker; Geoffrey W de Lisle; Bryce M Buddle
Journal:  Infect Immun       Date:  2003-01       Impact factor: 3.441

8.  Single dose of a vaccine based on DNA encoding mycobacterial hsp65 protein plus TDM-loaded PLGA microspheres protects mice against a virulent strain of Mycobacterium tuberculosis.

Authors:  K M Lima; S A Santos; V M F Lima; A A M Coelho-Castelo; J M Rodrigues; C L Silva
Journal:  Gene Ther       Date:  2003-04       Impact factor: 5.250

9.  Oral vaccination with Mycobacterium bovis BCG in a lipid formulation induces resistance to pulmonary tuberculosis in brushtail possums.

Authors:  Frank E Aldwell; Denise L Keen; Natalie A Parlane; Margot A Skinner; Geoffrey W de Lisle; Bryce M Buddle
Journal:  Vaccine       Date:  2003-12-08       Impact factor: 3.641

10.  Oral vaccination with subunit vaccines protects animals against aerosol infection with Mycobacterium tuberculosis.

Authors:  T Mark Doherty; Anja Weinrich Olsen; Laurens van Pinxteren; Peter Andersen
Journal:  Infect Immun       Date:  2002-06       Impact factor: 3.441

View more
  8 in total

Review 1.  Prospects in Mycobacterium bovis Bacille Calmette et Guérin (BCG) vaccine diversity and delivery: why does BCG fail to protect against tuberculosis?

Authors:  Juan I Moliva; Joanne Turner; Jordi B Torrelles
Journal:  Vaccine       Date:  2015-08-28       Impact factor: 3.641

2.  Lactoferrin modulation of BCG-infected dendritic cell functions.

Authors:  Shen-An Hwang; Jeffrey K Actor
Journal:  Int Immunol       Date:  2009-08-19       Impact factor: 4.823

3.  Influence of bovine lactoferrin on expression of presentation molecules on BCG-infected bone marrow derived macrophages.

Authors:  Shen-An Hwang; Marian L Kruzel; Jeffrey K Actor
Journal:  Biochimie       Date:  2008-04-27       Impact factor: 4.079

4.  Oral vaccination of guinea pigs with a Mycobacterium bovis bacillus Calmette-Guerin vaccine in a lipid matrix protects against aerosol infection with virulent M. bovis.

Authors:  Simon Clark; Martin L Cross; Allan Nadian; Julia Vipond; Pinar Court; Ann Williams; R Glyn Hewinson; Frank E Aldwell; Mark A Chambers
Journal:  Infect Immun       Date:  2008-06-02       Impact factor: 3.441

5.  Induction of Unconventional T Cells by a Mutant Mycobacterium bovis BCG Strain Formulated in Cationic Liposomes Correlates with Protection against Mycobacterium tuberculosis Infections of Immunocompromised Mice.

Authors:  Steven C Derrick; Idalia Yabe; Sheldon Morris; Siobhan Cowley
Journal:  Clin Vaccine Immunol       Date:  2016-07-05

6.  Formulation of a mmaA4 gene deletion mutant of Mycobacterium bovis BCG in cationic liposomes significantly enhances protection against tuberculosis.

Authors:  Steven C Derrick; Dee Dao; Amy Yang; Kris Kolibab; William R Jacobs; Sheldon L Morris
Journal:  PLoS One       Date:  2012-03-19       Impact factor: 3.240

Review 7.  Animals devoid of pulmonary system as infection models in the study of lung bacterial pathogens.

Authors:  Yamilé López Hernández; Daniel Yero; Juan M Pinos-Rodríguez; Isidre Gibert
Journal:  Front Microbiol       Date:  2015-02-04       Impact factor: 5.640

8.  Oral vaccination with lipid-formulated BCG induces a long-lived, multifunctional CD4(+) T cell memory immune response.

Authors:  Lindsay R Ancelet; Frank E Aldwell; Fenella J Rich; Joanna R Kirman
Journal:  PLoS One       Date:  2012-09-25       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.